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Abstract 
Renal cell carcinoma (RCC) is a highly vascularized tumor type, which is often associated 
with inactivated mutations in the von Hippel-Lindau gene that drives proangiogenic 
signaling pathways. As such, new therapies for the treatment of RCC have largely been 
focused on blocking angiogenesis. Sunitinib, an antiangiogenic tyrosine kinase inhibitor, is 
the most frequently used first-line drug for the treatment of RCC. Although treatment with 
sunitinib improves patient outcome considerably, acquired resistance will emerge in all 
cases. The molecular mechanisms of resistance to sunitinib are poorly understood, but in 
the past decade, several of these have been proposed. Lysosomal sequestration of sunitinib 
was reported as a potential resistance mechanism to sunitinib. In this review, the 
underlying molecular mechanisms of lysosomal sunitinib sequestration and the potential 
strategies to overcome this resistance are discussed to be able to further improve the 
treatment of RCC. 
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Introduction
Kidney cancer is one of the fastest growing 
cancers worldwide. Currently, it is the 
ninth most common cancer type in men 
and the 14th most common cancer type in 
women, with approximately 214,000 and 
124,000 patients, respectively. Incidence 
rates are higher in developed countries 
wherein up to half of the cases are 
discovered by chance (1). The most 
common renal RCC subtypes are clear cell 
(75%), papillary (15%), chromophobic (5%), 
and collecting duct carcinoma (2%) (2). In 
addition to the four main types of RCC, 
there are rare, ever expanding RCC 
subtypes that do not fit in any of these 
mentioned categories. 
In general, RCC is highly resistant to 
traditional cancer treatments, such as 
radiation therapy and chemotherapy (3). A 
better biological understanding of RCC has 
resulted in a rational development of 
targeted therapies, such as antiangiogenic 
tyrosine kinase inhibitors (TKIs). Currently, 
TKIs, such as sunitinib, pazopanib, and 
axitinib, are approved by the Food and 
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Drug Administration (FDA) for the 
treatment of RCC. Despite the clinical 
benefits, prolonged progression-free 
survival, and overall survival of sunitinib, 
patients develop resistance to sunitinib 
and eventually experience relapse (4). 
Several resistance mechanisms including 
upregulation of proangiogenic signaling 
pathways, increased AXL and MET 
expression (5), inadequate target inhibition, 
and resistance mediated by the tumor 
microenvironment or by the action of 
microRNAs have been reported. Recently, a 
new potential resistance mechanism to 
sunitinib, namely lysosomal sequestration, 
has been reported (6). In this review, this 
resistance mechanism and the approaches 
to overcome resistance to sunitinib by 
using this novel knowledge are discussed. 
Angiogenesis in RCC 
In RCC, which is one of the most 
vascularized tumors, the von Hippel-
Lindau (VHL) tumor suppressor gene is 
inactivated in 50-75% of the cases through 
mutations, hypermethylations, or loss of 
heterozygosity (7). As a consequence of the 
production of pVHL, the functional protein 
of the VHL gene is inhibited or decreased. 
pVHL plays a crucial role in the 
downregulation of the hypoxia-inducible 
factor 1 (HIF1) transcription factor, which 
subsequently decreases angiogenesis. 
Upon pVHL downregulation, HIF1 is 
accumulated, and an increase in the 
transcription of HIF1 target genes, such as 
vascular endothelial growth factor (VEGF) 
and platelet-derived growth factor (PDGF), 
is released. Receptors for VEGF (VEGFR) 
and PDGF (PDGFR) are key players in 
angiogenesis. VEGF mediates VEGFR 
regulation of vessel permeability, 
endothelial cell activation, survival, 
proliferation, invasion, and migration (8). 
For the maintenance and stabilization of 
newly formed vessels, VEGF alone is not 
sufficient, and it requires support from the 
surrounding periendothelial cells, such as 
vascular smooth muscles (VSMCs) and 
pericytes. The secretion of PDGF-B by the 
endothelial cells and the receptor tyrosine 
kinases of PDGF-B located on VSMC and 
pericytes are involved in this crosstalk with 
VEGFR. The frequent inactivation of VHL 
provided a rationale for the development of 
antiangiogenic drugs, such as sunitinib, for 
the treatment of RCC, which will be 
discussed in the next paragraph. 
Sunitinib 
Sunitinib (SU11248) is an oral multitargeted 
TKI that was granted accelerated FDA 
approval for the treatment of RCC and 
imatinib-resistant gastrointestinal tumor in 
2006, being the first TKI approved for two 
different indications at the same time. In 
2011, sunitinib was also approved by the 
FDA for the treatment of advanced 
pancreatic neuroendocrine tumors (9). 
Initially, sunitinib was developed as an 
antiangiogenic agent inhibiting VEGFR2 and 
PDGFR, the two major targets, expressed in 
endothelial cells and perivascular cells 
(pericytes). Later, sunitinib was also shown 
to inhibit KIT, FLT3, and RET kinases and 
many other kinases localized in tumor cells, 
resulting in antiproliferative and/or apoptotic 
effects of these cells (10). In addition, 
sunitinib has no preference for tyrosine or 
serine-threonine kinases, indicating its broad 
kinase inhibition profile (10, 11). Its direct 
antitumor activity may also be explained by 
the significant accumulation in tumor 
tissues at clinically relevant concentrations 
(6), despite 10-fold lower plasma 
concentrations. 
The clinical development of sunitinib for 
RCC was based on the encouraging data 
from the phase I trial, in which three of the 
four patients with RCC showed objective 
responses. Subsequently, a phase II trial 
was initiated for sunitinib, investigating its 
use as a second-line treatment for patients 
with cytokine-refractory metastatic RCC. In 
this phase II trial, 69 patients were 
enrolled and partial responses were 
observed in 40% and stable disease in 27% 
of patients. The overall median time to 
progression was 8.7 months (12). Because 
of these exceptional findings for a 
treatment-refractory disease as RCC at 
that time, a second phase II trial, in which 
106 patients were enrolled, was initiated to 
confirm these outcomes. 
Based on the findings of these two phase II 
studies, sunitinib received accelerated FDA 
approval in 2006. In both the phase II 
trials, the objective response rate (ORR) for 
sunitinib as a second-line therapy was 
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higher than that for cytokine therapy as a 
first-line treatment. Given the fact that the 
ORR for the first-line cytokine therapy is 
approximately only 15% and that no drug 
as a second-line treatment was able to show 
benefit for RCC patients in clinical trials, a 
phase III trial was initiated to investigate the 
use of sunitinib in the first-line setting. In 
total, 750 patients worldwide were included 
in this trial comparing sunitinib and 
interferon-α (IFNα) with each other. For 
sunitinib, ORR was 31%, whereas for IFNα 
this was only 6%. The median PFS was 11 
months for sunitinib versus 5 months for 
IFNα (13). After finishing this phase III trial, 
the FDA completed the approval of sunitinib 
in 2007 and included its use in the first-line 
setting for the treatment of RCC. 
Resistance mechanisms 
Despite the clinical benefits achieved, 
patients with cancer may be intrinsically 
resistant or may acquire resistance to 
treatment with sunitinib. Approximately 
70% of patients show clinical benefit to 
sunitinib but develop acquired resistance 
in 6-15 months, while 30% are intrinsically 
resistant (14). Understanding the 
molecular mechanism underlying intrinsic 
and acquired resistance to sunitinib may 
provide clues on how to circumvent this 
clinical problem. Several sunitinib 
resistance mechanisms, such as the 
upregulation of proangiogenic signaling 
pathways, increased tumor invasiveness 
and metastasis, activation of alternative 
signaling pathways, inadequate target 
inhibition, and resistance mediated by the 
tumor microenvironment or by the action 
of microRNAs, have been reported [for an 
extensive review, see the article by Joosten 
et al. (15)]. The evidence of most of these 
mechanisms has been derived from 
preclinical models, and their clinical 
relevance needs to be proven. 
One factor that seems to be very crucial in 
sunitinib resistance is tumor hypoxia. 
Inhibiting angiogenesis with VEGF-targeted 
agents not only results in stabilization or 
regression of the tumor but also renders 
tumor cells hypoxic, leading to HIF1 
accumulation (14). Subsequently, this 
causes upregulation of proangiogenic 
factors, such as VEGF that stimulates 
angiogenesis, cMET upregulation that 
increases tumor invasiveness and 
epithelial-to-mesenchymal transition, and 
stromal cell-derived factor-1 upregulation 
that recruits proangiogenic bone marrow-
derived cells. 
A recent study showed that chronic 
sunitinib treatment induced the activation 
of AXL and MET signaling and 
subsequently even promoted the 
prometastatic behavior of renal cancer cells 
and increased angiogenesis in a xenograft 
786-O mouse model (5). 
Besides the restoration of angiogenesis 
through the activation of alternative 
pathways, reduced bioavailability through 
increased efflux by drug pumps such as 
the ATP-binding cassette (ABC) superfamily 
or lysosomal sequestration leading to 
inadequate target inhibition may be 
another factor contributing to resistance of 
sunitinib. In the next paragraph, the 
lysosomal sunitinib sequestration is 
discussed in more detail. 
Lysosomal sequestration 
Lysosomes are acidic intracellular 
organelles containing acidic hydrolases 
capable of degrading biological 
macromolecules, such as nucleic acids, 
lipids, and proteins. In addition, lysosomes 
are involved in recycling defective 
organelles, exocytosis, apoptosis, and 
autophagy. Hydrophobic weak base 
chemotherapeutic drugs, such as 
doxorubicin, daunorubicin, mitoxantrone, 
and imidazoacridinones, have been shown 
to accumulate in lysosomes. Recently, this 
was also demonstrated for sunitinib in 
renal and colon cancer cells, after the 
observation was made that the intracellular 
sunitinib concentration was 10-fold higher 
in resistant cells than in sensitive cells, 
providing a new resistance mechanism for 
this TKI (6). The hydrophobic properties of 
sunitinib (log P = 5.2) allow the drug to 
cross cell membranes easily via passive 
diffusion. However, because sunitinib is a 
weak base (pKa = 8.95), it becomes 
protonated in an acidic environment and 
loses its ability to cross membranes. 
Therefore, upon entering into lysosomes, 
sunitinib is entrapped in its cationic state 
in these acidic organelles. Remarkably, 
despite the increased intracellular 
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sunitinib concentration in resistant cells, 
kinase activity was unaffected. p-Akt and 
p-ERK levels in resistant cells were similar 
to the levels in untreated parent cells. 
Increased sequestration of sunitinib in 
lysosomes of resistant tumors has also 
been demonstrated in in vivo experiments. 
The expression of lysosomal-associated 
membrane protein (LAMP)-1 and -2, which 
reflects lysosomal capacity, was found to 
be higher in sunitinib-resistant tumors 
when compared with that in parental 
tumors (16). Lysosomal sequestration as a 
resistance mechanism was also shown for 
other TKIs, such as gefitinib and lapatinib 
in immortalized human hepatocytes 
(Fa2N-4 cells) (17). In addition, pazopanib 
and erlotinib showed increased 
intracellular accumulation measured with 
liquid chromatography-tandem mass 
spectrometry system and an elevated 
expression of LAMP-1 and LAMP-2 in 
resistant renal (786-O) and colorectal 
cancer cells (HT29), suggesting an 
involvement of the lysosomal compartment 
(18). These compounds have the same 
chemical properties as sunitinib, being 
hydrophobic weak base TKIs (Table 1). 
Although lysosomal sequestration of 
sorafenib was not found in renal and 
colorectal cancer cells (17), it has been 
demonstrated in hepatocellular carcinoma 
(HCC) by Colombo et al. (19). Sorafenib 
does not belong to the same class of 
hydrophobic, membrane-permeable weak 
base as sunitinib, and therefore, a 
different mechanism could explain its 
lysosomal sequestration, probably an 
active involvement of drug pumps. 
The lysosomal sequestration of sunitinib 
and sorafenib was reported to be mediated 
by the ABC transporter P-glycoprotein 
(Pgp) (19). This drug pump actively 
effluxes various cytotoxic compounds from 
the cells for cytoprotection. Pgp expression 
was found not only in cell membranes but 
also in lysosomes, being involved in 
actively sequestering sunitinib into these 
organelles. On the surface of lysosomes, 
the transcription factor EB (TFEB) forms a 
complex with mammalian target of 
rapamycin (mTOR1) (mTORC1). When 
TFEB becomes phosphorylated at Ser211 
by mTORC1, it interacts with 14-3-3 and 
remains in the cytoplasm. However, as a 
consequence of aberrant lysosomal 
storage, cell starvation, or mTORC1 
inhibition, TFEB dissociates from the 
lysosome and translocates to the nucleus 
and increases the expression of genes 
encoding lysosomal proteins (20). 
Recently, it was found that lysosomal 
sequestration of hydrophobic weak base 
chemotherapeutics, including sunitinib, 
triggers TFEB-mediated lysosomal 
biogenesis, resulting in a significant 
increase in the number of lysosomes per 
cell. As a consequence, the efficiency of 
lysosomal drug sequestration and 
therefore multidrug resistance increases 
even further (21) (see Figure 1). 
Overcoming sunitinib resistance by 
disturbing lysosomal sequestration 
Lysosomal sequestration seems to eliminate 
the cytotoxic effect of sunitinib by 
decreasing drug concentrations at the 
intracellular target site. Therefore, a 
potential approach to overcome resistance 
to sunitinib may be combination treatment 
with drugs that circumvent lysosomal drug 
sequestration. A better understanding of the  
 
 
Table 1. Lysosomal sequestration of TKIs in several different cell lines 
 
Drug Calculated 
log P 
Calculated 
pKa 
(strongest 
basic) 
Lysosomal sequestration 
found in  
References 
Sunitinib 5.2 8.95 Renal and colon cancer cells (6) 
Gefitinib 3.2 7.20 Hepatocytes (17) 
Lapatinib 5.4 7.20 Hepatocytes (17) 
Pazopanib 3.6 5.07 Renal and colon cancer cells (18) 
Erlotinib 3.2 4.59 Renal and colon cancer cells (18) 
Sorafenib 4.34 2.03 Hepatocellular carcinoma (19) 
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Figure 1. Schematic summary model for hydrophobic weak base drug-induced lysosome-mediated 
drug resistance. Hydrophobic weak base drugs enter the lysosomes by simple diffusion and undergo 
protonation in the acidic lysosomal lumen, thereby becoming irreversibly sequestered in lysosomes 
and acidic intracellular vesicles such as late endosomes. In turn, lysosomal drug sequestration 
triggers TFEB-mediated lysosomal biogenesis, resulting in a significant increase in the number of 
lysosomes per cell. Increased lysosome number per cell enhances the efficiency of lysosomal drug 
sequestration, with lysosomes acting as a sink pulling hydrophobic weak base drugs away from their 
cellular target sites, thereby resulting in MDR (21). 
mechanisms underlying lysosome-
mediated drug resistance, which have been 
discussed in the previous paragraph, is 
therefore of great importance. The extent of 
lysosomal drug sequestration has been 
shown to depend on the pH gradient 
between the acidic luminal pH of the 
lysosome and that of the cytoplasm (22). In 
this respect, lysosomal drug accumulation 
can be reversed with agents that alkalinize 
lysosomes, such as bafilomycin A1, a H+-
ATPase inhibitor. In in vitro experiments, 
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this compound was shown to reverse 
lysosomal sunitinib sequestration. However, 
this compound is too toxic for in vivo 
treatment. Therefore, in mice, chloroquine, 
which inhibits lysosomal function by raising 
lysosomal pH, was used (16). Currently, 
chloroquine and hydroxychloroquine are the 
only clinically available inhibitors of 
autophagy. 
Despite the findings and the potential 
mechanism of resistance as described 
above, concanamycin A, a vacuolar-type 
H+-ATPase inhibitor, reduced the amount 
of cell death induced by sunitinib in breast 
cancer MCF7 cells dramatically due to 
relocalization of sunitinib into the cytosol 
(23). This suggests that lysosomal 
sequestration seems to be essential for the 
cytotoxic activity of sunitinib. The 
discrepancy that lysosomal sequestration 
explains sunitinib resistance on one hand 
and is important for antitumor activity of 
sunitinib on the other hand could be cell-
type specific. This also indicates that 
resistance to an antitumor agent is a 
complex process and involves several 
different molecular mechanisms. 
Alternative data showing that lysosomal 
accumulation of sunitinib is involved in 
resistance are provided by the reports 
showing that the overexpression of Pgp in 
lysosomes enhances intralysosomal drug 
sequestration. Subsequently, inhibition of 
this drug pump with verapamil restored 
sensitivity to TKIs, including sunitinib, 
especially when administrated after drug 
preincubation. An explanation that during 
the preincubation phase, anticancer drugs 
are being trapped in Pgp-positive 
lysosomes was given by the authors. 
Blocking Pgp activity by subsequent 
incubation with the drug/verapamil 
combination allows drug diffusion from the 
culture medium and lysosome into the 
cytoplasm (Figure 2). As a consequence, 
the intracellular drug concentration is 
increased (19). The clinical use of 
verapamil is limited due to its cardiac 
toxicity. Alternatively, due to the fact that 
verapamil undergoes extensive hepatic 
first-pass metabolism, it is theoretically 
possible to avoid this side effect by using 
intrahepatic injections in combination with 
chemoembolization (24, 19). 
Switching to another TKI when resistance to 
sunitinib occurs is a practical clinical strategy 
to consider. However, this option is not 
always feasible and often does not solve the 
problem due to cross-resistance. For most of 
the antiangiogenic TKIs, including pazopanib, 
erlotinib, and lapatinib, cross-resistance in 
sunitinib-resistant RCC cells was found (18). 
The antitumor activity of sorafenib and the 
mTOR inhibitor, everolimus, did not decrease 
upon sunitinib resistance. Switching to these 
drugs is therefore a potential option when 
patients with RCC are resistant to sunitinib 
treatment. 
Sequential therapy with everolimus is 
preferred over combining this drug with 
sunitinib. As described in the previous 
paragraph, lysosomal sunitinib sequestration 
increases via TFEB-mediated lysosomal 
biogenesis (21). This can be achieved 
through mTOR inhibition. In addition, the 
combination of sunitinib with everolimus 
was associated with significant toxicities (25). 
An intriguing observation made in the 
laboratory is that when exposed to light, 
sequestered sunitinib caused immediate 
destruction of the lysosomes, resulting in the 
release of sunitinib and cell death. Although 
combining sunitinib with phototherapy could 
therefore be an interesting approach to 
overcome sunitinib resistance caused by 
lysosomal sequestration (26), its practical 
use is very limited due to the superficial and 
local treatment options with phototherapy. A 
more practical approach for patients with 
metastatic disease requiring systemic 
exposure is urgently needed. Several 
interesting combination therapies to 
overcome sunitinib resistance in metastatic 
renal cancer are being explored in preclinical 
and clinical studies (27). It is of high interest 
to see the outcome of the phase I trial 
(NCT00813423) in which sunitinib is 
combined with hydroxychloroquine in 
patients with advanced solid tumors that 
have not responded to chemotherapy to 
better understand whether disturbing 
lysosomal sunitinib sequestration is clinically 
involved in its resistance. 
Conclusions 
Sunitinib is a very active first-line drug for 
the treatment of RCC. However, due to the 
chemical properties of sunitinib, this 
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Figure 2. Hypothesized mechanism of the enhanced efficacy of drug pretreatment before 
verapamil administration and PGP blockade. A. HCC cells expressing active PGP can expel a drug 
(e.g., sunitinib) from the cytoplasm or store it in lysosomes. B. Blocking PGP with verapamil 
before the coadministration of sunitinib and verapamil allows the drugs to enter the cell and 
diffuse into cytoplasm/nucleus. C. If sunitinib is used for pretreatment, it is stored in giant 
lysosomes, and after the coadministration of sunitinib and verapamil and subsequent PGP 
blockade, the drugs can enter the cytoplasm/nucleus from both extracellular space and the 
lysosomes (19). 
compound becomes sequestered in 
lysosomes, preventing the drug from 
reaching its target. After being treated for a 
period of time, most patients with RCC 
develop resistance to sunitinib potentially 
as a consequence of drug accumulation in 
lysosomes. Some studies have investigated 
the molecular mechanism of this novel 
resistance mechanism in more detail, 
providing clues for the concomitant 
treatment of sunitinib with drugs that 
interfere with lysosomal function. 
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